Cargando…
Preclinical studies of toxicity and anti-cholangiocarcinoma activity of the standardized capsule formulation of Atractylodes lancea (Thunb.) DC
BACKGROUND: Cholangiocarcinoma (CCA), the adenocarcinoma of the biliary duct, is commonly reported in Asia, with the highest incidence in northeastern Thailand. Chemotherapy of CCA has been limited by the lack of effective chemotherapeutic drugs. A series of previous in vitro and in vivo studies sup...
Autores principales: | Plengsuriyakarn, Tullayakorn, Kotawong, Kanawut, Karbwang, Juntra, Na-Bangchang, Kesara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10245495/ https://www.ncbi.nlm.nih.gov/pubmed/37287012 http://dx.doi.org/10.1186/s12906-023-03992-z |
Ejemplares similares
-
Research and Development of Atractylodes lancea (Thunb) DC. as a Promising Candidate for Cholangiocarcinoma Chemotherapeutics
por: Na-Bangchang, Kesara, et al.
Publicado: (2017) -
Phase I clinical trial to evaluate the safety and pharmacokinetics of capsule formulation of the standardized extract of Atractylodes lancea
por: Na-Bangchang, Kesara, et al.
Publicado: (2021) -
Apoptotic and Anti-metastatic Effects of Atractylodes lancea (Thunb.) DC. in a Hamster Model of Cholangiocarcinoma
por: Sonsomnuek, Paradon, et al.
Publicado: (2022) -
A randomized placebo-controlled phase I clinical trial to evaluate the immunomodulatory activities of Atractylodes lancea (Thunb) DC. in healthy Thai subjects
por: Kulma, Inthuon, et al.
Publicado: (2021) -
Atractylodes lancea for cholangiocarcinoma: Modulatory effects on CYP1A2 and CYP3A1 and pharmacokinetics in rats and biodistribution in mice
por: Muhamad, Nadda, et al.
Publicado: (2022)